Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 2434 • ACR Convergence 2025
Specificity of Cell-bound T Cell Biomarkers (TC4d, TIgG, TIgM) in Differentiating SLE from ANA-Associated Rheumatic Diseases
Vasileios Kyttaris¹, Sepehr Taghavi², Clayton Nagle³, Christine Schleif³, Brittany Partain⁴ and Tyler O'Malley⁵, ¹Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, ²Exagen Inc, Escondido, CA, ³Exagen, Carlsbad, CA, ⁴Exagen, Boston, MA, ⁵Exagen, Vista, CA
Background/Purpose: We previously validated T Cell-bound C4d (TC4d), T Cell-bound IgG (TIgG), and T Cell-bound IgM (TIgM) biomarkers, demonstrating high sensitivity and specificity for differentiating…
Abstract Number: 2416 • ACR Convergence 2025
Direct and Indirect Costs Associated with Damage Accrual: Results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort
Megan Barber¹, John Hanly², Murray Urowitz³, Ian Bruce⁴, Yvan St-Pierre⁵, Caroline Gordon⁶, Sang-Cheol Bae⁷, Juanita Romero-Diaz⁸, Francisco Sanchez-Guerrero⁹, Sasha Bernatsky¹⁰, Daniel Wallace¹¹, David A. Isenberg¹², Anisur Rahman¹², Joan Merrill¹³, Paul Fortin¹⁴, Dafna D. Gladman¹⁵, Michelle Petri¹⁶, Ellen Ginzler¹⁷, Mary Anne Dooley¹⁸, Rosalind Ramsey-Goldman¹⁹, Susan Manzi²⁰, Andreas Jönsen²¹, Graciela Alarcón²², Ronald van Vollenhoven²³, Cynthia Aranow²⁴, Meghan mackay²⁵, Guillermo Ruiz-Irastorza²⁶, S. Sam Lim²⁷, Murat Inanç²⁸, Kenneth Kalunian²⁹, Soren Jacobsen³⁰, Christine Peschken⁸, Diane Kamen³¹, Anca Askanase³² and Ann Clarke¹, ¹Division of Rheumatology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ²Dalhousie University, Halifax, NS, Canada, Halifax, NS, Canada, ³University of Toronto, Toronto, ON, Canada, ⁴Centre for Public Health, Faculty of Medicine, Health and Life Sciences, Queen’s University Belfast, Belfast, United Kingdom, ⁵Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ⁶Department of Inflammation and Ageing, College of Medicine and Health, University of Birmingham, Birmingham, United Kingdom, ⁷Hanyang University Medical Center, Seoul, South Korea, ⁸University of Manitoba, Winnipeg, MB, Canada, ⁹University Health Network/Sinai Health system, Toronto, ON, Canada, ¹⁰Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ¹¹Cedars Sinai Medical Center, Studio City, CA, ¹²University College London, London, United Kingdom, ¹³Oklahoma Medical Research Foundation, Oklahoma City ⁷³¹⁰⁴, OK, ¹⁴Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada, ¹⁵Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ¹⁶Johns Hopkins University School of Medicine, Timonium, MD, ¹⁷SUNY Downstate Health Sciences University, New York, NY, ¹⁸UNC physician network, Chapel Hill, NC, ¹⁹Northwestern University Feinberg School of Medicine, Chicago, IL, ²⁰Lupus Center of Excellence, Autoimmunity Institute, Allegheny Health Network, Pittsburgh, PA, ²¹Department of Clinical Sciences, Lund University, Lund, Sweden, ²²The University of Alabama at Birmingham, Oakland, CA, ²³Department of Rheumatology, Amsterdam University Medical Centre, Amsterdam, Netherlands, ²⁴Institute of Molecular Medicine, Feinstein Institutes for Medical Research, Manhasset, NY, ²⁵Feinstein Institutes for Medical Research, Manhasset, NY, ²⁶Biobizkaia Health Research Institute, Barakaldo, Spain, ²⁷Emory University School of Medicine, Atlanta, GA, ²⁸Istanbul University, Istanbul, Turkey, ²⁹UC San Diego, La Jolla, CA, ³⁰Rigshospitalet, Copenhagen, Denmark, ³¹Medical University of South Carolina, Johns Island, SC, ³²Columbia University Medical Center, New York, NY
Background/Purpose: We reported partial direct healthcare costs associated with damage accrual in the SLICC Inception Cohort (Barber M. Arthritis Care Res 2020;72:1800). We have supplemented…
Abstract Number: 2397 • ACR Convergence 2025
Analytical Performance of a Fully Automated Multiplexed Microarray Immunoassay for the Simultaneous Detection of Fifteen Autoantibodies Associated with Connective Tissue Diseases in a Reference Laboratory in Southern France
Guillaume Nardella¹, Gerber Gomez², Christian Fischer² and Claire Monat¹, ¹Inovie Labosud Provence, Specialized Autoimmunity Analyses, Marseille, France, ²Scientific & Medical Affairs, AliveDx Suisse SA, Eysins, Switzerland
Background/Purpose: Autoantibodies are key diagnostic markers in autoimmune connective tissue diseases (CTD). Conventional testing often requires multiple single-measurand assays, which can be labor-intensive and time-consuming.…
Abstract Number: 2382 • ACR Convergence 2025
Autoimmune Hemolytic Anemia in SLE: A Real-World National Cohort Study
Bana Shawareb¹, Muhannad Haddadin¹, lindsay Frumker², Keri Ann Pfeil³, Meghan Gump³, Ansaam Daoud⁴ and Omer Pamuk⁵, ¹Cleveland Clinic Akron General, Akron, OH, ²Case Western Reserve University, Cleveland, ³University Hospitals Cleveland Medical Center/Case Western Reserve University, Cleveland, OH, ⁴Case Western Reserve University/University Hospitals, Cleveland, OH, ⁵University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH
Background/Purpose: Autoimmune hemolytic anemia (AIHA) is a rare but serious hematologic manifestation of SLE. The prognostic implications of AIHA, particularly long-term mortality and organ involvement,…
Abstract Number: 2209 • ACR Convergence 2025
Pregnancy outcomes in Systemic Lupus Erythematosus: Insights from a multicenter Spanish Study on the impact of antiphospholipid antibodies and APS
cristiana Sieiro¹, Jose Ordas Martínez², Ana Merino³, Helena Amar Muñoz⁴, Stefanie Burger⁵, Ignacio Braña Abascal⁵, Carmen Jose Mendéz⁶, Raquel Dos Santos Sobrín⁷, Jose Luis Puga Guzman⁷, Ricardo Blanco⁸ and Víctor Taboada Martínez³, ¹Univrsity of Manchester, Manchester, United Kingdom, ²Complejo Asistencial Universitario de León, León, Spain, ³Hospital Universitario Marqués de Valdecilla, Santader, Spain,, Santander, Spain, ⁴Hospital General Universitario Gregorio Marañón, Rheumatology, Madrid, Spain, Madrid, Spain, ⁵Hospital Universitario Central de Asturias, Rheumatology, Oviedo, Spain, Oviedo, Spain, ⁶Complexo Hospitalario Universitario A Coruña, Rheumatology, A Coruña, Spain, Coruña, Spain, ⁷Hospital Universitario de Santiago de Compostela, Rheumatology, Santiago de Compostela,, Santiago de Compostela, Spain, ⁸Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain
Background/Purpose: Pregnancy in patients with systemic lupus erythematosus (SLE) is associated with significant maternal and obstetric risks, particularly in the context of antiphospholipid syndrome (APS).…
Abstract Number: 1925 • ACR Convergence 2025
Associations between Representation and Quality in Clinical Trials for Systemic Lupus Erythematosus
Joshua Skydel¹, Anna Leland², Reshma Ramachandran³, Fotios Koumpouras³ and Joshua Wallach², ¹Yale-New Haven Hospital, New Haven, CT, ²Rollins School of Public Health, Atlanta, GA, ³Yale School of Medicine, New Haven, CT
Background/Purpose: Drug development in SLE is informed by US Food and Drug Administration recommendations for study design, enrollment, and efficacy endpoints. However, persistent challenges to…
Abstract Number: 1848 • ACR Convergence 2025
DS-7011a, An Anti-TLR7 Antagonistic Monoclonal Antibody, Suppresses Human Immune Cells and Multiple Cytokines/Chemokines Related to the Pathogenesis of SLE
Nanako NIshiyama¹, Atsushi Manno¹, Tomohiro Honda², Shigeko Uryu¹, Yuichiro Imamura², Ryutaro Fukui³, Yusuke Murakami⁴, Kensuke Miyake⁵ and Yoshiaki Tomimori⁶, ¹Daiichi Sankyo Co., Ltd., Tokyo, Tokyo, Japan, ²Daiichi Sankyo Co., Ltd., Tokyo, Japan, ³Chiba University, Tokyo, Japan, ⁴Musashino University, Tokyo, Japan, ⁵Chiba University, Chiba, Japan, ⁶Daiichi Sankyo, Inc., Basking Ridge, NJ
Background/Purpose: Toll-like receptor (TLR) 7 is a pattern recognition receptor that recognizes nucleic acids and is implicated in the pathogenesis of systemic lupus erythematosus (SLE).…
Abstract Number: 1831 • ACR Convergence 2025
Distinct Proteomic Signature Predicts Post-MMF Withdrawal Flares in Systemic Lupus Erythematosus Patients
Christian Wright¹, Miles Smith², Rufei Lu², Catriona Wagner³, Aleksandra Bylinska², Carla Guthridge², Nicholas Domingez², Susan Macwana², Wade DeJager⁴, Marci Beel⁵, Joan Merrill⁶, Eliza Chakravarty², Ellen Goldmuntz⁷, Study Team ALE⁰⁶ Clinical⁸, Judith James² and Joel Guthridge², ¹University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Oklahoma city, OK, ³Oklahoma Medical Research Foundation, Santa Cruz, CA, ⁴Oklahoma Medical Research Foundation, Oklahoma City, ⁵Oklahoma Medical Research Foun, Oklahoma City, OK, ⁶Oklahoma Medical Research Foundation, Oklahoma City ⁷³¹⁰⁴, OK, ⁷NIAID/ NIH, Washington, DC, ⁸Autoimmunity Center of Excellence, Oklahoma City, OK
Background/Purpose: : Systemic Lupus Erythematosus (SLE) follows a characteristic relapsing-remitting course with unpredictable flares interspersed with periods of relative quiescence. Mycophenolate mofetil (MMF) has emerged…
Abstract Number: 1720 • ACR Convergence 2025
Comparison of Mortality Trends in Adults with Systemic Lupus Erythematosus and Cutaneous Lupus Erythematosus: A 21-Year Analysis Using CDC WONDER DATABASE.
Khadija Mohib¹, Rameez Qasim², Zaiya Waseem³, Shaheer Ahmad⁴ and Ahmad Ali Hussain⁵, ¹Kirk Kerkorian School of Medicine at UNLV, Las Vegas, NV, ²Allama Iqbal Medical College Lahore, Lahore, Pakistan, ³AtlantiCare Regional Medical Center, New Jersey, ⁴Allama Iqbal Medical College, Lahore, Pakistan, ⁵Allama Iqbal Medical College Lahore, Lahore
Background/Purpose: Systemic Lupus Erythematosus (SLE) and Cutaneous Lupus Erythematosus (CLE) are chronic autoimmune diseases with significant morbidity and mortality, collectively accounting for approximately 5,000 deaths…
Abstract Number: 1639 • ACR Convergence 2025
Concordance of Self-Reported Physical Functioning and Physical Performance in SLE: A Cross-Cohort Analysis
Laura Plantinga¹, Mrinalini Dey², Jessica Fitzpatrick³, Maria Dall'Era⁴, Charmayne Dunlop-Thomas⁵, Courtney Hoge⁵, S. Sam Lim⁶, C. Barrett Bowling⁷, Jinoos Yazdany³ and Patti Katz⁸, ¹University of California, San Francisco, San Francisco, CA, ²Centre for Rheumatic Diseases, King's College London, London, United Kingdom, ³UCSF, San Francisco, CA, ⁴Division of Rheumatology, University of California, San Francisco, CA, ⁵Emory University, Atlanta, GA, ⁶Emory University School of Medicine, Atlanta, GA, ⁷Duke University, Durham, NC, ⁸UCSF, San Rafael, CA
Background/Purpose: Assessment of self-reported physical functioning is common in SLE and essential for high-quality SLE care. However, because many factors may influence self-reported physical function…
Abstract Number: 1539 • ACR Convergence 2025
The Impact Of Interferon Signature On Anifrolumab Efficacy And Safety In Systemic Lupus Erythematosus: A Systematic Review And Meta-analysis
Muhammad Usman Hashmi¹, Paramarajan Piranavan², Yasmeen Sufi³, Zaira Nasir⁴, Zainab Azhar⁵, Shamaem Tariq⁵, Hamas Ul Hudaibia⁵, IMRAN SAEED⁶, Aayet Zulfiqar⁵, Natasha Rasool² and Anum Faiz⁷, ¹Rahmah Academy of Research Excellence, Islamabad, Pakistan., Islamabad, Pakistan, ²University of Kentucky, Louisville, KY, ³Karachi Medical & Dental College, Karachi, Karachi, Pakistan, ⁴Rawalpindi Medical University,Rawalpindi, Pakistan., Islamabad, Pakistan, ⁵Rawalpindi Medical University,Rawalpindi, Pakistan., Rawalpindi, Pakistan, ⁶Nishtar Medical University,Multan, Pakistan., Multan, Pakistan, ⁷Jinnah Hospital Lahore, Pakistan, Lahore, Pakistan
Background/Purpose: Type I interferon (IFN) signaling is central to systemic lupus erythematosus (SLE) pathogenesis, and anifrolumab, a monoclonal antibody targeting the IFN-α receptor (IFNAR), has…
Abstract Number: 1522 • ACR Convergence 2025
Outcomes of Continuing Hydroxychloroquine following Renal Transplant in Patients with Lupus Nephritis: A retrospective Cohort Study using the TrinetX database
Carlos Pena¹, Irene Tan², Rafal Ali³, Arthur Lau⁴, Shahrzad Abdollahi⁵, Fabian Rodriguez Quinonez⁶ and Marianne Meshreky⁷, ¹Jefferson Einstein Philadelphia, Wynnewood, PA, ²Einstein Healthcare Network Philadelphia - Jefferson Health, Bala Cynwyd, PA, ³Jefferson Einstein Philadelphia, Lansdale, PA, ⁴Jefferson Einstein Hospital, Maple Glen, PA, ⁵Jefferson Einstein Hospital, Philadelphia, PA, ⁶Einstein Medical Center Philadelphia, Philadelphia, PA, ⁷St. Mary's Hospital, Philadelphia
Background/Purpose: Evidence of kidney disease occurs in up to one half of patients with SLE, and approximately 10% of the patients with lupus nephritis (LN)…
Abstract Number: 1498 • ACR Convergence 2025
Both Race and Socioeconomic Status Affect Mortality in SLE
Gursimran Kaur¹, Daniel Goldman², Andrea Fava³, Laurence Magder⁴ and Michelle Petri², ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University School of Medicine, Timonium, MD, ³Johns Hopkins University, Baltimore, MD, ⁴University of Maryland, Baltimore, Baltimore, MD
Background/Purpose: A recent meta-analysis found an overall 2.87-fold increase in all-cause mortality in systemic lupus erythematosus (SLE) with cause-specific increases in renal disease, infections, cardiovascular…
Abstract Number: 1481 • ACR Convergence 2025
Duffy Antigen Screening in Systemic Lupus Erythematosus Patients with Neutropenia: A Quality Improvement Initiative
Divya Sudireddy¹, Jason Yang², Huseyin Berk Degirmenci³, Eva Petrow² and Michael York⁴, ¹Boston Medical Center, Westborough, MA, ²Boston Medical Center, Boston, MA, ³Boston University Medical Center, Boston, MA, ⁴Boston University, Boston, MA
Background/Purpose: Laboratory monitoring for patients with systemic lupus erythematosus (SLE) is essential for assessing disease activity and detecting treatment-related adverse effects, including cytopenias. Neutropenia in…
Abstract Number: 1301 • ACR Convergence 2025
Prevalence, Clinical and Genetic Risk Factors, and Time to Cataract Development in Childhood-onset Systemic Lupus Erythematosus
Sirikarn Tangcheewinsirikul¹, Zhaoyu Ding², Nicholas Chan³, Daniela Dominguez³, Andrea Knight⁴, Deborah Levy¹, Lawrence Ng⁵, Earl Silverman¹, Ruud Verstegen¹ and Linda Hiraki¹, ¹The Hospital for Sick Children, Toronto, ON, Canada, ²SickKids Research Institute, Toronto, ON, Canada, ³The Hospital for Sick Children, Toronto, Canada, ⁴Hospital for Sick Children, Toronto, ON, Canada, ⁵The Hospital for Sick Children, Toronto, Canada, Toronto, ON, Canada
Background/Purpose: Cataracts are a significant ocular complication in childhood-onset systemic lupus erythematosus (cSLE). This study aimed to assess the prevalence, time to cataract development, and…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].